BioCentury
DATA GRAPHICS | Data Byte

Biotech venture 1Q24: less activity but bigger round sizes

Disclosed venture financings sunk to their lowest number in six years, but larger round sizes kept the total raised stable

By Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst
April 19, 2024 10:18 PM UTC

So far this year, most signs have (finally) pointed to a biotech recovery.

On the public investment side, BioCentury’s latest Public Markets Preview found 1Q24 was the best quarter for raising capital since 1Q21, the start of biotech’s bear market. In addition to an uptick in follow-on financings signaling a return to a healthier market, PIPEs posted their biggest single-quarter total since BioCentury began tracking financings in 1993...